Ronald Witteles MD
Adult Congenital Heart Disease, Cardiac Electrophysiology, Heart Failure & Transplantation
Assistant Professor, Medicine - Cardiovascular Medicine, Stanford University Medical Center
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Witteles is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 2004 - 2007
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2000 - 2003
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000
Certifications & Licensure
- CA State Medical License 2001 - 2027
- OR State Medical License 2020 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Most Compassionate Doctor American Registry
- Fellow (FACC) American College of Cardiology
Clinical Trials
- BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS) Start of enrollment: 2004 Mar 01
- Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure Start of enrollment: 2008 Apr 01
- Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation Start of enrollment: 2021 Apr 01
Publications & Presentations
PubMed
- Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis.Marianna Fontana, John L Berk, Brian Drachman, Pablo Garcia-Pavia, Mazen Hanna
Circulation. Heart Failure. 2025-03-31 - Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy.Mathew S Maurer, Ronald M Witteles, Pablo Garcia-Pavia, Farooq H Sheikh, Caroline Morbach
Journal of the American College of Cardiology. 2025-03-11 - 1 citationsThe Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis.Gracia Fahed, John Isaiah Jimenez, Marina I Adrianzen Fonseca, Jonathan Hu, Gabriela Spencer-Bonilla
JACC. Heart Failure. 2025-03-01
Abstracts/Posters
- Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep ResponsesRonald Witteles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL AmyloidosisRonald Witteles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Authored Content
- Summary of Clinical Trials for the Prevention and Treatment of Cardiomyopathy Related to Anthracyclines and HER2-Targeted AgentsJuly 2020
- Summary of Clinical Trials for the Prevention and Treatment of Cardiomyopathy Related to Anthracyclines and HER2-Targeted AgentsJuly 2020
Press Mentions
- Vutrisiran Improves Cardiac Amyloidosis Endpoints Regardless of Disease SeverityApril 2nd, 2025
- Vutrisiran Snags FDA Approval for TTR Amyloidosis CardiomyopathyMarch 21st, 2025
- Vutrisiran, with the FDA’s Sign-off, Joins the Fray for ATTR-CMMarch 21st, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
